Methods of Administration (Dosage and Administration)
Route of Administration: Primarily subcutaneous injection (SC) (abdomen/thigh/upper arm, rotating sites); intravenous infusion is limited to specific clinical trials (e.g., 0.01–0.25 mg/kg/h).
Approved Dosage (Forzinity, Barth Syndrome): 40 mg SC once daily (TAZPOWER/Open Extension).
Clinical Trial Dosage Reference: Primary Mitochondrial Myopathy (MMPOWER-3): 40 mg SC/day × 24 weeks; Heart Failure (PROGRESS-HF): IV 0.005–0.25 mg/kg/h × 4 h; Renal Artery Stenosis: 0.05 mg/kg/h IV.
Research Grade/Unapproved Use: Commonly used in community "longevity/mitochondrial support" regimens: 1–10 mg SC/day or periodically used for 8–12 weeks, discontinued for 2–4 weeks. This is an unverified human kinetic dose and not medical advice.
Preparation (Research Grade Lyophilized Powder): Reconstitute with sterile water/antibacterial water; Clinical finished products should be used directly according to the instructions.
Contraindications/Cautions: Pregnancy and lactation (insufficient data); Hypersensitivity to this product; Barth-related indications are off-label/experimental; Research-grade raw materials are not suitable for human use.
Application Scenarios and Research Evidence: Based on extensive preclinical and clinical research evidence, SS-31 shows broad application prospects in the following areas closely related to mitochondrial dysfunction:
1. Cardiovascular Diseases
Myocardial ischemia-reperfusion injury: Studies have shown that SS-31 can reduce mitochondrial ROS production under ischemic conditions, increase ATP synthesis, and improve cardiac function.
Heart Failure and Cardiomyopathy: In animal models, SS-31 improved cardiac function and reduced pulmonary hypertension caused by aortic coarctation. In Barth syndrome (a hereditary cardiomyopathy caused by cardiolipin deficiency), a strategy targeting cardiolipin has theoretical potential.
2. Neurodegenerative Diseases
Alzheimer's Disease (AD): In cell and animal models expressing mutant amyloid precursor protein (APP), SS-31 can protect neurons from Aβ-induced mitochondrial dysfunction and cell death, restore axonal mitochondrial transport, and alleviate oxidative damage.
Parkinson's Disease and Other Inflammation-Related Neurological Injuries: SS-31 can inhibit NLRP3 inflammasome activation, suppress the production of inflammatory factors such as IL-1β in microglia stimulated by LPS, and prevent excessive mitochondrial division. Studies have shown that novel SS-31 derivatives (such as 5f and 5g) exhibit stronger antineuritis activity in this regard than the parent compound.
3. Metabolic Diseases and Muscle Aging
Type 2 Diabetes: In leukocytes of patients with type 2 diabetes, SS-31 can upregulate SIRT1 and downregulate TNFα and NFκB, thereby reducing inflammatory markers.
4. Sarcopenia and Chemotherapy-Induced Muscle Damage: In aged mouse models, SS-31 restored muscle mitochondrial structure and function, improved exercise endurance, and alleviated muscle tissue damage induced by the chemotherapy drug doxorubicin.
5. Age-Related Vascular Diseases
Brain Microvascular Protection: A 2023 study showed that SS-31 treatment in aged mice rescued age-related changes in the brain microvascular proteome, suggesting its potential in protecting the microvessels of aging brains.
6. Current Status and Challenges of Clinical Translation
Despite encouraging preclinical data, some Phase III clinical trials failed to meet their primary efficacy endpoints, highlighting the complexity of translating basic research into clinical results in this field. This also suggests the need for more precise patient screening and disease stratification strategies in the future.
Storage Conditions
SS-31 is a peptide compound, and its stability must be maintained during storage:
Storage Temperature: Recommended storage temperature is −20°C.
Stability: Under recommended storage conditions, its stability can be maintained for ≥2 years.
Precautions: The solution should be prepared and used immediately or dispensed and stored at a low temperature, away from light. Avoid repeated freeze-thaw cycles to prevent degradation and inactivation.
FAQ
Q: What is the minimum order quantity?
A: The minimum order quantity is 10 bottles/set.
Q: How long does it take to ship?
A: In-stock orders will be shipped within 24 hours.
Q: What purity level can you provide?
A: Standard purity 99%.
Q: Which courier service do you use?
A: FedEx, DHL, UPS, and postal services are available.
Q: How long does shipping take?
A: Approximately 10-15 days.
Q: Can you provide a COA (Certificate of Authorization) quality inspection report and HPLC (High-Performance Computing) report?
A: Yes, all goods undergo professional testing before shipment.
Q: Do you support OEM branding?
A: OEM branding service is supported, subject to the minimum order quantity requirement.
Q: What are the after-sales service procedures? A: After the customer signs for the goods, if the quality problem is confirmed to be caused by our production, they can enjoy free replacement or refund. We adhere to the service principle of pragmatism and responsibility, actively respond to and properly handle all kinds of issues, without shirking responsibility or avoiding problems, and do our best to protect the rights and interests of our customers.
Q: What payment methods are available?
A: We support bank transfer, Bitcoin, Transferwise, and Xoom.
Methods of Administration (Dosage and Administration)
Route of Administration: Primarily subcutaneous injection (SC) (abdomen/thigh/upper arm, rotating sites); intravenous infusion is limited to specific clinical trials (e.g., 0.01–0.25 mg/kg/h).
Approved Dosage (Forzinity, Barth Syndrome): 40 mg SC once daily (TAZPOWER/Open Extension).
Clinical Trial Dosage Reference: Primary Mitochondrial Myopathy (MMPOWER-3): 40 mg SC/day × 24 weeks; Heart Failure (PROGRESS-HF): IV 0.005–0.25 mg/kg/h × 4 h; Renal Artery Stenosis: 0.05 mg/kg/h IV.
Research Grade/Unapproved Use: Commonly used in community "longevity/mitochondrial support" regimens: 1–10 mg SC/day or periodically used for 8–12 weeks, discontinued for 2–4 weeks. This is an unverified human kinetic dose and not medical advice.
Preparation (Research Grade Lyophilized Powder): Reconstitute with sterile water/antibacterial water; Clinical finished products should be used directly according to the instructions.
Contraindications/Cautions: Pregnancy and lactation (insufficient data); Hypersensitivity to this product; Barth-related indications are off-label/experimental; Research-grade raw materials are not suitable for human use.
Application Scenarios and Research Evidence: Based on extensive preclinical and clinical research evidence, SS-31 shows broad application prospects in the following areas closely related to mitochondrial dysfunction:
1. Cardiovascular Diseases
Myocardial ischemia-reperfusion injury: Studies have shown that SS-31 can reduce mitochondrial ROS production under ischemic conditions, increase ATP synthesis, and improve cardiac function.
Heart Failure and Cardiomyopathy: In animal models, SS-31 improved cardiac function and reduced pulmonary hypertension caused by aortic coarctation. In Barth syndrome (a hereditary cardiomyopathy caused by cardiolipin deficiency), a strategy targeting cardiolipin has theoretical potential.
2. Neurodegenerative Diseases
Alzheimer's Disease (AD): In cell and animal models expressing mutant amyloid precursor protein (APP), SS-31 can protect neurons from Aβ-induced mitochondrial dysfunction and cell death, restore axonal mitochondrial transport, and alleviate oxidative damage.
Parkinson's Disease and Other Inflammation-Related Neurological Injuries: SS-31 can inhibit NLRP3 inflammasome activation, suppress the production of inflammatory factors such as IL-1β in microglia stimulated by LPS, and prevent excessive mitochondrial division. Studies have shown that novel SS-31 derivatives (such as 5f and 5g) exhibit stronger antineuritis activity in this regard than the parent compound.
3. Metabolic Diseases and Muscle Aging
Type 2 Diabetes: In leukocytes of patients with type 2 diabetes, SS-31 can upregulate SIRT1 and downregulate TNFα and NFκB, thereby reducing inflammatory markers.
4. Sarcopenia and Chemotherapy-Induced Muscle Damage: In aged mouse models, SS-31 restored muscle mitochondrial structure and function, improved exercise endurance, and alleviated muscle tissue damage induced by the chemotherapy drug doxorubicin.
5. Age-Related Vascular Diseases
Brain Microvascular Protection: A 2023 study showed that SS-31 treatment in aged mice rescued age-related changes in the brain microvascular proteome, suggesting its potential in protecting the microvessels of aging brains.
6. Current Status and Challenges of Clinical Translation
Despite encouraging preclinical data, some Phase III clinical trials failed to meet their primary efficacy endpoints, highlighting the complexity of translating basic research into clinical results in this field. This also suggests the need for more precise patient screening and disease stratification strategies in the future.
Storage Conditions
SS-31 is a peptide compound, and its stability must be maintained during storage:
Storage Temperature: Recommended storage temperature is −20°C.
Stability: Under recommended storage conditions, its stability can be maintained for ≥2 years.
Precautions: The solution should be prepared and used immediately or dispensed and stored at a low temperature, away from light. Avoid repeated freeze-thaw cycles to prevent degradation and inactivation.
FAQ
Q: What is the minimum order quantity?
A: The minimum order quantity is 10 bottles/set.
Q: How long does it take to ship?
A: In-stock orders will be shipped within 24 hours.
Q: What purity level can you provide?
A: Standard purity 99%.
Q: Which courier service do you use?
A: FedEx, DHL, UPS, and postal services are available.
Q: How long does shipping take?
A: Approximately 10-15 days.
Q: Can you provide a COA (Certificate of Authorization) quality inspection report and HPLC (High-Performance Computing) report?
A: Yes, all goods undergo professional testing before shipment.
Q: Do you support OEM branding?
A: OEM branding service is supported, subject to the minimum order quantity requirement.
Q: What are the after-sales service procedures? A: After the customer signs for the goods, if the quality problem is confirmed to be caused by our production, they can enjoy free replacement or refund. We adhere to the service principle of pragmatism and responsibility, actively respond to and properly handle all kinds of issues, without shirking responsibility or avoiding problems, and do our best to protect the rights and interests of our customers.
Q: What payment methods are available?
A: We support bank transfer, Bitcoin, Transferwise, and Xoom.
Hot Tags: ss-31 10mg/vial enhances metabolism and treats cardiovascular and neurological diseases., China ss-31 10mg/vial enhances metabolism and treats cardiovascular and neurological diseases. manufacturers, suppliers, factory
